Chemistry and Special Chemistry testing
Agency: | |
---|---|
Level of Government: | Federal |
Category: |
|
Opps ID: | NBD00159791150780147 |
Posted Date: | Dec 1, 2023 |
Due Date: | Dec 11, 2023 |
Source: | https://sam.gov/opp/ec17a44e13... |
- Contract Opportunity Type: Special Notice (Original)
- All Dates/Times are: (UTC-06:00) CENTRAL STANDARD TIME, CHICAGO, USA
- Original Published Date: Nov 30, 2023 05:27 pm CST
- Original Response Date: Dec 11, 2023 12:00 pm CST
- Inactive Policy: 15 days after response date
- Original Inactive Date: Dec 26, 2023
-
Initiative:
- None
- Original Set Aside:
- Product Service Code: 6550 - IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS
-
NAICS Code:
- 325413 - In-Vitro Diagnostic Substance Manufacturing
-
Place of Performance:
Biloxi , MS 39534USA
The Southern Markets Contracting Division (SMCD), San Antonio, Texas, intends to award a firm-fixed-price (FFP) sole source contract to Siemens Healthcare Diagnostics of Tarrytown, New York to conduct Chemistry and Special Chemistry testing for Keesler Medical Center, Keesler Air Force Base, Mississippi. As a Cost-per-Reportable-Test (CPRT) vehicle, the contractor also provides all equipment, consumables, and services necessary to perform the required testing. The contract will be awarded under the authority of Federal Acquisition Regulation (FAR) 13.501. The applicable NAICS code for this requirement is 325413, In-Vitro Diagnostics Substance Manufacturing. The Small Business Size Standard is 1,250 employees. Siemens Healthcare Diagnostics is an "other-than-small business." The contract will be awarded on or before 1 January 2024.
NOTE: This contract will be issued for a performance period of 1 January 2024 -30 September 2024, with one (1) twelve-month option period. The Government intends to issue a competitive solicitation on a full-and-open basis for these tests, with full performance on the resultant contract to start in FY 2026.
This notice is not a request for competitive quotes. All responsible sources may submit a capability statement, which shall be considered by the agency before the intended award date to determine if any other entity is capable of performing the required testing. Interested sources who submit data are responsible for appropriately marking information if it is proprietary in nature. In order for the Government to consider another source, the capability statement must demonstrate the source's ability to 1) provide the required testing; 2) deliver, install, and validate the analyzer(s) to ensure patient-ready testing; and 3) ability to connect to the Defense Health Agency/Military Health System network.
The Government shall not reimburse interested sources for any information provided. No requests for capability briefings will be honored as a result of this notice and any information provided will not be used as part of any subsequent solicitation requirement. No telephonic inquires will be honored. A determination by the Government not to compete with this proposed contract based upon responses to this notice is solely within the discretion of the Government.
NOTE: INTERESTED VENDORS MUST RESPOND TO THIS NOTICE TO THE BELOW POCs ON OR BEFORE 11 DECEMBER 2023 BY NOON CENTRAL TIME IN ORDER TO BE CONSIDERED.
- CONTRACTING OFFICE-SAN ANTONIO 7800 W IH-10, STE 235
- SAN ANTONIO , TX 78230
- USA
- Carolynn Benn
- carolynn.j.benn.civ@health.mil
- Phone Number 2108684971
- David Erpelding
- david.k.erpelding.civ@health.mil
- Nov 30, 2023 05:27 pm CSTSpecial Notice (Original)
TRY FOR FREE
Not a USAOPPS Member Yet?
Get unlimited access to thousands of active local, state and federal government bids and awards in All 50 States.